About: Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats
Creator	Chan, Philip Simon, Melissa Hillyer, Christopher Bandy, Utpala Hogan, Joseph Huard, Richard Jin, Daniel King, Ewa Luchsinger, Larry Nesbitt, Daniel Vargas, Matthew
Source	MedRxiv
abstract	Epidemic projections and public health policies addressing Coronavirus disease (COVID)-19 have been implemented without data reporting on the seroconversion of the population since scalable antibody testing has only recently become available. We measured the percentage of severe acute respiratory syndrome- Coronavirus-2 (SARS-CoV-2) seropositive individuals from 2,008 blood donors drawn in the state of Rhode Island (RI). We utilized multiple antibody testing platforms, including lateral flow immunoassays (LFAs), enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). We report than an estimated seropositive rate of RI blood donors of approximately 0.6% existed in April-May of 2020. These data imply that seroconversion, and thus infection, is likely not widespread within this population. Daily new case rates peaked in RI in late April 2020. We conclude that IgG LFAs and HTSAs are suitable to conduct seroprevalence assays in random populations. More studies will be needed using validated serological tests to improve the precision and report the kinetic progression of seroprevalence estimates.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1101/2020.07.20.20157743
has license	medrxiv
sha1sum (hex)	15720129ea01919290ace007a55b4041a8a1af97
schema:url	https://doi.org/10.1101/2020.07.20.20157743
resource representing a document's title	Low Seroprevalence of SARS-CoV-2 in Rhode Island Blood Donors Determined using Multiple Serological Assay Formats
resource representing a document's body	covid:15720129ea01919290ace007a55b4041a8a1af97#body_text
is schema:about of	named entity 'HEALTH POLICIES' named entity 'measured' named entity 'public health' named entity 'seroconversion' named entity 'COVID' named entity 'Serological' named entity 'pseudovirus' named entity 'preprint' named entity 'antibodies' named entity 'seroprevalence' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity 'preprint' named entity 'Biosensor' named entity 'seropositivity' named entity 'plasma' named entity 'demographic' named entity 'peer review' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'silica' named entity 'vaccine' named entity 'CC-BY-NC-ND 4.0' named entity 'sensitivity and specificity' named entity 'Antibodies' named entity 'IgG' named entity 'SARS-CoV-1' named entity 'IgM' named entity 'COVID' named entity 'viral infections' named entity 'Antibodies' named entity 'SARS-CoV-2' named entity 'IgM' named entity 'CC-BY-NC-ND 4.0' named entity 'immunogenic' named entity 'Rhode Island' named entity 'plasma donation' named entity 'high-throughput' named entity 'antigens' named entity 'antibody' named entity 'antibodies' named entity 'immunogenic' named entity 'seroprevalence' named entity 'seropositive' named entity 'antibody testing' named entity 'Receptor Binding Domain' named entity 'medRxiv' named entity 'immune responses' named entity 'seroconversion' named entity 'seroprevalence' named entity 'preprint' named entity 'social distancing' named entity 'Antibody' named entity 'ELISA assay' named entity 'antiviral' named entity 'IgG' named entity 'IgM' named entity 'preprint' named entity 'seroprevalence' named entity 'Biosensor' named entity 'antibodies' named entity 'seroprevalence' named entity 'adaptive immunity' named entity 'preprint' named entity 'ELISAs' named entity 'preprint' named entity 'IgM' named entity 'viral proteins' named entity 'seropositive' named entity 'antibodies' named entity 'high levels' named entity 'medRxiv' named entity '450 nm' named entity 'Rhode Island' named entity 'serological tests'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software